Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

“…Patients must be informed of adverse events so that they can contact medical personnel as soon as possible 57 .…”

“…Depending on the symptoms, it might be necessary to administer medication. Antihistamines, corticosteroids, and if necessary, epinephrine and bronchodilators should be administered, and oxygen should be readily available 57 . In the case of a severe reaction, treatment should not be continued.…”

“…In the case of a severe reaction, treatment should not be continued. However, with a mild reaction, treatment can be resumed the same day [57][58][59] . In many cases, a mild-to-moderate reaction will resolve after a brief interruption of treatment and administration of appropriate medication 60 .…”

Management and Preparedness for Infusion and Hypersensitivity Reactions

“…The taxanes paclitaxel and docetaxel produce reactions that are clinically similar to type 1 hypersensitivity, but evidence suggests that these reactions are not mediated by IgE [9,10]. Instead, these reactions may be caused by direct effects on immune cells or other mechanisms.…”

“…For monoclonal antibodies, reducing the infusion rate by half (e.g., from 100 mg/hour to 50 mg/hour for rituximab or from a maximum rate of 5 ml/ minute to 2.5 ml/minute for cetuximab) is recommended [20,27]. Desensitization protocols have been used with some success in patients who experience severe hypersensitivity reactions to taxanes [9,11,39].…”